- Report
- August 2024
- 175 Pages
Global
From €4775EUR$5,000USD£3,993GBP
- Report
- October 2024
- 140 Pages
Global
From €2388EUR$2,500USD£1,997GBP
- Report
- July 2024
Global
From €4632EUR$4,850USD£3,873GBP
- Report
- March 2024
- 200 Pages
Global
From €3963EUR$4,150USD£3,314GBP
- Report
- February 2024
- 110 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- January 2024
- 109 Pages
United States
€3343EUR$3,500USD£2,795GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$3,926USD£3,029GBP
- Report
- March 2025
- 50 Pages
Global
From €2531EUR$2,650USD£2,116GBP
- Report
- March 2025
- 50 Pages
Global
From €2531EUR$2,650USD£2,116GBP
Montelukast is a leukotriene receptor antagonist used to treat asthma and allergic rhinitis. It is a prescription drug that is taken orally, usually once a day. Montelukast works by blocking the action of leukotrienes, which are chemicals that cause inflammation in the airways. This helps to reduce the symptoms of asthma and allergic rhinitis, such as wheezing, coughing, and difficulty breathing. Montelukast is generally well tolerated and has few side effects.
Montelukast is one of several drugs used to treat asthma and allergic rhinitis. Other drugs used to treat these conditions include inhaled corticosteroids, long-acting beta agonists, and anti-IgE therapy. Montelukast is often used in combination with other drugs to provide the best possible treatment.
Several companies produce and market Montelukast, including Merck & Co., Inc., Teva Pharmaceuticals, and Mylan Pharmaceuticals. These companies produce generic versions of the drug, as well as branded versions. Montelukast is also available in combination with other drugs, such as fluticasone and salmeterol. Show Less Read more